SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001694665-23-000020
Filing Date
2023-03-16
Accepted
2023-03-16 07:10:48
Documents
15
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20230316.htm   iXBRL 8-K 26976
2 EX-99.1 a2022q4earningsrelease.htm EX-99.1 103537
6 evelosign.jpg GRAPHIC 8150
7 evlo-20230316_g1.jpg GRAPHIC 7885
  Complete submission text file 0001694665-23-000020.txt   306963

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20230316.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20230316_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20230316_pre.xml EX-101.PRE 13047
9 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20230316_htm.xml XML 4266
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 23737111
SIC: 2834 Pharmaceutical Preparations